Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108M
-
Number of holders
-
109
-
Total 13F shares, excl. options
-
23.6M
-
Shares change
-
+2.41M
-
Total reported value, excl. options
-
$703M
-
Value change
-
+$73.9M
-
Number of buys
-
69
-
Number of sells
-
-47
-
Price
-
$29.82
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q1 2017
128 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock as of Q1 2017.
Aclaris Therapeutics, Inc. - Common Stock (ACRS) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23.6M shares
of 108M outstanding shares and own 21.8% of the company stock.
Largest 10 shareholders include Vivo Capital, LLC (2.86M shares), FMR LLC (1.65M shares), Sofinnova Management VIII, L.L.C. (1.54M shares), PERCEPTIVE ADVISORS LLC (1.26M shares), FRANKLIN RESOURCES INC (1.26M shares), PointState Capital LP (971K shares), Polar Capital LLP (971K shares), Cormorant Asset Management, LLC (800K shares), BlackRock Inc. (781K shares), and VANGUARD GROUP INC (712K shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.